Loading
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (1 ops.)
Latest filing published 17 Jun 2026 for GoodRx Holdings, Inc..
Filing timeline
BuySaleRonald E. Bruehlman
Insider track record
Disclosed buys
3
Disclosed sells
1
Signal history
Closed purchases
Market purchases
3
Positive at T+90
33%
Median T+90
-9.7%
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -6.7%Entry US$228.27 · Close at T+365 US$212.98
- -0.7%Entry US$228.64 · Close at T+365 US$227.03
- +54.6%Entry US$161.04 · Close at T+365 US$248.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Ronald E. Bruehlman: trading record in brief
Ronald E. Bruehlman has filed 34 filings between February 17, 2016 and June 17, 2026: 22 at Iqvia Holdings Inc. and 4 at IMS Health Holdings, Inc., both under the role "See Remarks", and 8 at GoodRx Holdings, Inc., as a Director. Most of it is equity pay, with 28 grants and 1 option exercise.
The open-market trades are very small: 3 purchases, 2 of them with an amount, EUR 3,602 in total, and one sale of EUR 885 on October 25, 2021. The two largest purchases are EUR 2,706 on July 20, 2021 and EUR 895 on September 23, 2021. Purchases make up 75% of open-market trades, but over a volume of four trades.
The yearly pace runs from 2 filings in 2020 and 2021 to 6 in 2022, 2024 and 2025. Six filings fall in the last twelve months, with no purchase and no sale. The median publication delay is 2 days.
At Iqvia, four colleagues' trades (Ari Bousbib, Kevin C. Knightly, W. Richard Staub and TPG Group Holdings (SBS) Advisors, Inc.) fall within 30 days of a trade by Bruehlman, each time in the opposite direction.
Companies and markets linked to Ronald E. Bruehlman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations34 total
73,434 sharesClass A Common StockSEC:0001809519-26-000125:0
4,642 shares0Class A Common StockSEC:0001809519-26-000117:0
6,801 shares@ US$187.4915.3% of flowCommon StockSEC:0001628280-26-006952:1
16,335 shares0Common StockSEC:0001628280-26-006952:0
18,251 shares0Class A Common StockSEC:0001809519-26-000003:0
21,691 sharesClass A Common StockSEC:0001809519-25-000145:0
57,050 shares0Class A Common StockSEC:0001809519-25-000090:0
907 shares@ US$206.9710.0% of flowCommon StockSEC:0001478242-25-000037:0
2,201 shares@ US$203.436.0% of flowCommon StockSEC:0001478242-25-000008:1
6,286 shares0Common StockSEC:0001478242-25-000008:0
10,653 shares0Class A Common StockSEC:0001809519-25-000002:0
20,503 shares0Class A Common StockSEC:0001809519-24-000202:1
1,128 shares0Class A Common StockSEC:0001809519-24-000202:0
907 shares@ US$218.202.6% of flowCommon StockSEC:0001478242-24-000027:1
1,033 shares@ US$218.2011.5% of flowCommon StockSEC:0001478242-24-000027:0
10,514 shares@ US$215.4129.7% of flowCommon StockSEC:0001478242-24-000016:1
24,141 shares0Common StockSEC:0001478242-24-000016:0
2,588 shares@ US$216.2928.2% of flowCommon StockSEC:0001478242-23-000089:0
614 shares@ US$222.841.8% of flowCommon StockSEC:0001478242-23-000028:1
717 shares@ US$230.318.5% of flowCommon StockSEC:0001478242-23-000028:0
2,588 shares@ US$233.2132.8% of flowCommon StockSEC:0001478242-22-000090:0
4 shares@ US$256.930.0% of flowCommon StockSEC:0001478242-22-000043:1
4 shares@ US$262.820.0% of flowCommon StockSEC:0001478242-22-000043:0
Canonical exit: 22 Dec 2021 (T+90)
5,869 shares0Common StockSEC:0001478242-22-000022:1
13 shares@ US$245.320.1% of flowCommon StockSEC:0001478242-22-000022:0
Canonical exit: 18 Oct 2021 (T+90)
25 of 34 declarations
